Pamela Dudkiewicz

No ORCID on file · 5 papers in corpus · active 2004-2017

Study types

  • article 5
article 2017
·doi:10.1182/blood.v130.suppl_1.5423.5423

Abstract Introduction and Case studies. The treatment of multiple myeloma (MM) has drastically changed over the past decade with significantly improved progression free as well as overall survival. Despite the advent of multiple treatment o…

article 2011
·doi:10.1179/102453311x12902908412075

There is no good alternative therapy available for elderly patients with advanced myeloproliferative disorders (MPD) who failed on conventional therapies and are not candidates for bone marrow transplant. We report here an effective therapy…

article 2007
·doi:10.1182/blood.v110.11.3222.3222

Abstract Introduction: In ITP, platelets opsonized with antibodies are phagocytosed by macrophages. Activation of macrophages often triggers aggravation or relapses of ITP as demonstrated following vaccination, infections. G-CSF stimulates …

article 2006
·doi:10.1182/blood.v108.11.4887.4887

Abstract BACKGROUND: Myeloproliferative disorders (MPD) are a group of chronic proliferations of mutated stem cells leading to bone marrow failure and extramedullary hematopoiesis with splenomegaly. Although bone marrow transplant can be an…

article 2004
·doi:10.1182/blood.v104.11.4748.4748

Abstract MPD is a clonal stem cell disorder encompassing essential thrombocythemia (ET), polycythemia vera (PV), myelofibrosis (MF), chronic myelogenous leukemia (CML). Chemotherapy has been a mainstay of therapy for the treatment of MPD bu…